Stockscreener 앱 받기
4.84
3.64%
0.17
시간 외 거래:
4.75
-0.09
-1.86%
전일 마감가:
$4.67
열려 있는:
$4.78
하루 거래량:
708.09K
Relative Volume:
1.91
시가총액:
$385.47M
수익:
$12.14M
순이익/손실:
$-99.50M
주가수익비율:
-3.5754
EPS:
-1.3537
순현금흐름:
$-56.37M
1주 성능:
+13.35%
1개월 성능:
+31.52%
6개월 성능:
+258.52%
1년 성능:
+508.04%
1일 변동 폭
$4.32
$5.05
1주일 범위
$4.27
$5.26
52주 변동 폭
$0.75
$5.54
Prelude Therapeutics Inc Stock (PRLD) Company Profile
명칭
Prelude Therapeutics Inc
전화
(302) 467-1280
주소
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
4.84 | 371.93M | 12.14M | -99.50M | -56.37M | -1.3537 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2024-03-13 | 개시 | JMP Securities | Mkt Outperform |
| 2024-02-20 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | 개시 | Jefferies | Buy |
| 2022-03-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-02-28 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-10-08 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-04-26 | 개시 | H.C. Wainwright | Buy |
| 2021-03-09 | 개시 | Barclays | Overweight |
| 2020-11-20 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-10-20 | 개시 | BofA Securities | Buy |
| 2020-10-20 | 개시 | Goldman | Neutral |
| 2020-10-20 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Prelude Therapeutics Inc 주식(PRLD)의 최신 뉴스
PRLD Initiates Coverage On Prelude Therapeutics -- Price Target Announced at $9.00 - GuruFocus
D. Boral Capital Initiates Prelude Therapeutics(PRLD.US) With Buy Rating, Announces Target Price $9 - Moomoo
Prelude Therapeutics (PRLD) price target increased by 19.35% to 6.29 - MSN
Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer - Yahoo Finance
Prelude Therapeutics (NASDAQ:PRLD) Rating Increased to Hold at Zacks Research - MarketBeat
Prelude Therapeutics (NASDAQ: PRLD) outlines 2026 proxy votes on directors, pay and auditor - Stock Titan
Short Interest in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Decreases By 22.1% - MarketBeat
HC Wainwright Issues Positive Estimate for PRLD Earnings - MarketBeat
RA Capital reports 7.88M-share Prelude Therapeutics (PRLD) stake - Stock Titan
Prelude Therapeutics (PRLD) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
H.C. Wainwright raises Prelude Therapeutics price target to $8 By Investing.com - Investing.com Canada
PRLD Maintained by HC Wainwright & Co. -- Price Target Raised to $8 - GuruFocus
HC Wainwright Issues Positive Forecast for Prelude Therapeutics (NASDAQ:PRLD) Stock Price - MarketBeat
Prelude Therapeutics (NASDAQ:PRLD) Director David Bonita Buys 2,815,315 Shares - MarketBeat
Prelude Therapeutics (NASDAQ:PRLD) Director Buys $12,499,998.60 in Stock - MarketBeat
Insider Purchase: Director at $PRLD Buys 1,689,189 Shares - Moomoo
Orbimed entities acquire $12.5m in Prelude Therapeutics stock By Investing.com - Investing.com Canada
Prelude Therapeutics director David P. Bonita acquires $12.5 million in stock - Investing.com
Prelude Therapeutics director David P. Bonita acquires $12.5 million in stock By Investing.com - Investing.com South Africa
Orbimed entities acquire $12.5m in Prelude Therapeutics stock - Investing.com
OrbiMed funds add Prelude Therapeutics (PRLD) shares at $4.44 in offering - Stock Titan
OrbiMed funds boost Prelude Therapeutics (NASDAQ: PRLD) stake with 2.82M-share buy - Stock Titan
Prelude Therapeutics Enters Underwriting for $85.5 Million Equity Offering Led by RA Capital - TradingView
Prelude Therapeutics (PRLD) Unveils Promising Preclinical Data f - GuruFocus
Prelude Therapeutics (PRLD) Launches $90M Public Offering with S - GuruFocus
Prelude Therapeutics Shares Rise on Positive Preclinical Data for Breast Cancer Drug - Moomoo
Prelude Therapeutics Unveils Promising Preclinical Data for First-in-Class Oral KAT6A Degrader PRT13722 in HR+/HER2- Breast Cancer at AACR 2026 12 - Minichart
Prelude Therapeutics prices $90M equity offering - MSN
Prelude Therapeutics prices $90M stock offering at $4.44/share By Investing.com - Investing.com Canada
Prelude Therapeutics presents preclinical data on breast cancer drug By Investing.com - Investing.com Canada
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering - ChartMill
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 - Yahoo Finance
Prelude Therapeutics names Charles Morris as chief medical officer By Investing.com - Investing.com Australia
Prelude Therapeutics Appoints Dr. Charles Morris as Chief Medical Officer to Advance Precision Oncology Pipeline - Minichart
Prelude Therapeutics (PRLD) Appoints New Chief Medical Officer - GuruFocus
Prelude Therapeutics Appoints Veteran Oncologist as New CMO - TipRanks
Prelude Therapeutics names Charles Morris as chief medical officer - Investing.com
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer - The Manila Times
New CMO joins Prelude Therapeutics (NASDAQ: PRLD) as pipeline advances - Stock Titan
Bull Bear: Is Prelude Therapeutics Incorporated stock a good pick for beginners2026 Stock Rankings & Capital Efficiency Focused Ideas - baoquankhu1.vn
Activity Recap: Whats the beta of Prelude Therapeutics Incorporated stockQuarterly Trade Report & Safe Capital Investment Plans - baoquankhu1.vn
Aug Swings: What is the Moat Score of Prelude Therapeutics Incorporated2026 Earnings Impact & Weekly Stock Breakout Alerts - baoquankhu1.vn
Prelude Therapeutics (NASDAQ:PRLD) Shares Up 4.3%Still a Buy? - MarketBeat
Retail Surge: Is Prelude Therapeutics Incorporated a turnaround story2026 Drop Watch & Consistent Income Trade Recommendations - baoquankhu1.vn
PRLD Technical Analysis | Trend, Signals & Chart Patterns | PRELUDE THERAPEUTICS INC (NASDAQ:PRLD) - ChartMill
Loss Report: How do insiders feel about Prelude Therapeutics IncorporatedExit Point & Scalable Portfolio Growth Methods - baoquankhu1.vn
United Health Group, Viacom among market cap stock movers on Tuesday - Investing.com
IPO Launch: Will Prelude Therapeutics Incorporated stock go up in YEARMarket Performance Recap & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Is Prelude (PRLD) Stock Declining | Price at $4.08, Down 7.27%Expert Breakout Alerts - Newser
Prelude Therapeutics Incorporated (PRLD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Prelude Therapeutics Inc (PRLD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.25%
자본화:
|
볼륨(24시간):